CDKN2A and head and neck squamous cell carcinoma: Fifth, the pre:ada combination has limited potency in untransformed bronchial epithelial cells and IMR90 human fibroblasts, in comparison to HNSCC cell lines bearing TP53 and CDKN2A mutations.